Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Description of Drug Utilization and Assessment of Impact of Saxagliptin on Health Status of Patients With Type 2 Diabetes in France

NCT01552005 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01552005
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01552005 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Description of Drug Utilization and Assessment of Impact of Saxagliptin on Health Status of Patients With Type 2 Diabetes in France
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
May 31, 2012
Completion date
June 30, 2015
Enrollment
1,000 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus (t2d)